Compare · BNGO vs BRKR
BNGO vs BRKR
Side-by-side comparison of Bionano Genomics Inc. (BNGO) and Bruker Corporation (BRKR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNGO and BRKR operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BRKR is the larger of the two at $8.87B, about 666.5x BNGO ($13.3M).
- Over the past year, BNGO is down 69.3% and BRKR is up 37.4% - BRKR leads by 106.7 points.
- BRKR has been more active in the news (10 items in the past 4 weeks vs 8 for BNGO).
- BRKR has more recent analyst coverage (22 ratings vs 5 for BNGO).
- Company
- Bionano Genomics Inc.
- Bruker Corporation
- Price
- $1.15-2.95%
- $55.74-2.69%
- Market cap
- $13.3M
- $8.87B
- 1M return
- -10.16%
- +29.01%
- 1Y return
- -69.33%
- +37.36%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 8
- 10
- Recent ratings
- 5
- 22
Bionano Genomics Inc.
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. Bionano Genomics, Inc. has a procurement and collaboration agreement with NuProbe, Inc. for research and product development in the fields of reproductive health and oncology liquid biopsies. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Latest BNGO
- Bionano Genomics Inc. filed SEC Form 8-K: Leadership Update
- GENERAL COUNSEL Dixon Jonathan V. covered exercise/tax liability with 24 shares, decreasing direct ownership by 9% to 239 units (SEC Form 4) (for withholding tax)
- CHIEF OPERATING OFFICER Oldakowski Mark covered exercise/tax liability with 27 shares, decreasing direct ownership by 3% to 868 units (SEC Form 4) to satisfy withholding tax
- CHIEF MEDICAL OFFICER Chaubey Alka covered exercise/tax liability with 24 shares, decreasing direct ownership by 4% to 620 units (SEC Form 4) (for withholding tax)
- Principal Accounting Officer Adamchak Mark covered exercise/tax liability with 7 shares, decreasing direct ownership by 3% to 253 units (SEC Form 4) (withholding obligation)
- Bionano Genomics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures
- Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia
- SEC Form 4 filed by Director Rajkovic Aleksandar
- SEC Form 4 filed by Director Linney Yvonne
Latest BRKR
- Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
- Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
- Wolfe Research resumed coverage on Bruker
- Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
- SEC Form SD filed by Bruker Corporation
- Amendment: Bruker Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Champalimaud Foundation's Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI
- Bruker Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Bernard Thierry was granted 2,886 shares (SEC Form 4)
- EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19 and sold $87,800 worth of shares (2,000 units at $43.90) as part of a pre-agreed trading plan (SEC Form 4)